TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22372591
Drug: Estradiol valerate
Normalized name: Estradiol Valerate
DrugBank: Estradiol valerate (DB13956)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Estradiol valerate 2 mg daily
Study: 22372591
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of testosterone undecanoate and estradiol valerate
Study: 20451681
Drug: Anakinra 100
Normalized name: ANAKINRA 100MG INJ,SYRINGE,1ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anakinra 100 mg/day subcutaneously for 14 days
Study: 12477078
Drug: Dimetindene (H1‐receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dimetindene (H1‐receptor antagonist) plus cimetidine (H2‐receptor antagonist)
Study: 15520068
Drug: Single-agent doxorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-agent doxorubicin
Study: 7597425
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of doxorubicin and paclitaxel
Study: 1575171
Drug: Quinapril (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quinapril (20 mg dose)
Study: 6134626
Drug: Syrup of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Syrup of ipecac
Study: 27005470
Drug: Specific movement
Normalized name: Pacific halibut
DrugBank: Pacific halibut (DB10616)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Specific movement control exercise (SMCE) combined with manual therapy
Study: 27005470
Drug: General exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: General exercise combined with manual therapy
Study: 13680197
Drug: Displacement injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Displacement injection of 0.01 mg/kg of unlabelled flumazenil
Study: 7723358
Drug: isradipine 2.5
Normalized name: isradipine 2.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: isradipine 2.5 mg twice daily
Study: 1687425
Drug: atenolol 100
Normalized name: atenolol 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: atenolol 100 mg daily
Study: 7273647
Drug: Chemotherapy (randomised
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy (randomised between MOPP and LOPP) for patients with splenic involvement
Study: 31935382
Drug: Transdermal contraceptive
Normalized name: VCF Contraceptive
DrugBank: Nonoxynol-9 (DB06804)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transdermal contraceptive patch with newly sourced adhesive component (test)
Study: 31935382
Drug: EVRA patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: EVRA patch (reference)
Study: 28600161
Drug: Healthy Living
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Healthy Living Problem‐Solving (HELPS) intervention consisting of six group sessions conducted approximately monthly interspersed with individualized coaching calls.
Study: 25112845
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg sulodexide daily for 12 months
Study: 25112845
Drug: Placebo (matching
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (matching dose) daily for 12 months
Study: 21413691
Drug: Lecithin formulation
Normalized name: Lecithin
DrugBank: Lecithin (DB15834)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lecithin formulation (Meriva)
Study: 19109001
Drug: Gentian violet
Normalized name: Gentian Violet
DrugBank: Gentian violet cation (DB00406)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gentian violet aqueous solution 0.5%
Study: 11506055
Drug: 15 g
Normalized name: 15 g/31 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 g AG per day
Study: 11506055
Drug: 30 g
Normalized name: Lancet Unilet 30 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 g AG per day
Study: 11506055
Drug: AG (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: AG (15 g and 30 g)
Study: 9760014
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhaled by Rotahaler (Becotide Rotacaps)
Study: 9760014
Drug: Beclomethasone dipropionate
Normalized name: Beclomethasone Dipropionate
DrugBank: Beclomethasone dipropionate (DB00394)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Beclomethasone dipropionate inhaled by Cyclohaler (Beclomethasone Cyclocaps)
Study: 9760014
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rescue medication use in Rotahaler group
Study: 8583466
Drug: Moexipril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril monotherapy (7.5 or 15 mg once daily)
Study: 8583466
Drug: Moexipril combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril combined with hydrochlorothiazide (7.5 or 15 mg daily with 25 mg hydrochlorothiazide)
Study: 8583466
Drug: Moexipril monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moexipril monotherapy or combination therapy
Study: 2515971
Drug: Clonidine administration
Normalized name: Clonidine
DrugBank: Clonidine (DB00575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clonidine administration
Study: 29419533
Drug: Ergocalciferol 50,000
Normalized name: ergocalciferol 50,000 intl units oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ergocalciferol 50,000 IU once weekly for 8 weeks then once monthly for 4 months
Study: 26147153
Drug: HBX (HYBENX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBX (HYBENX® Oral Tissue Decontaminant™) in association with sub‐gingival ultrasonic debridement (UD)
Study: 26147153
Drug: HBX (HYBENX®
Approvals — FDA: no, EMA: no, PMDA: no
Description: HBX (HYBENX® Oral Tissue Decontaminant™) as monotherapy
Study: 26147153
Drug: Combined HBX-UD
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined HBX-UD treatment
Study: 17328819
Drug: Garlic group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Garlic group (400 mg garlic, 1 mg allicin, twice daily)
Study: 17328819
Drug: Anethum group
Normalized name: Anethum graveolens leaf extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anethum group (650 mg, twice daily)
Study: 15167450
Drug: Irbesartan (an
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irbesartan (an inhibitor of angiotensin II type 1 (AT1) receptors)
Study: 12749519
Drug: Celecoxib 200
Normalized name: celecoxib 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Celecoxib 200 mg QD
Study: 7972803
Drug: Injection into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the splenic artery (n=34)
Study: 7972803
Drug: Injection into
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Injection into the superior mesenteric artery (SMA) (n=37)
Study: 24491463
Drug: Intravenous magnesium
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous magnesium (MgSO4 50mg/kg in 100 mL of normal saline over 15 min before anesthesia induction, followed by an infusion of 15 mg/kg/hour)
Study: 21689089
Drug: NT-proBNP level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: NT-proBNP level ≥160ng/l
Study: 16503677
Drug: High-CHO diet
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-CHO diet (6.5 g CHO kg body mass(‐1))
Study: 16503677
Drug: Moderate-CHO diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate-CHO diet (4.4 g CHO kg body mass(‐1))
Study: 12757968
Drug: Cognitive-behavioral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive-behavioral treatment group
Study: 30900008
Drug: Phendimetrazine 210
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phendimetrazine 210 mg
Study: 30900008
Drug: Cocaine (0,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocaine (0, 20, 40, and 80 mg intranasal)
Study: 28751519
Drug: Intra-arterial treatment
Normalized name: methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intra-arterial treatment
Study: 21262413
Drug: Cognitive Behavioral
Normalized name: Mahana Parallel Digital Cognitive Behavioral Therapy Mobile Application for Irritable Bowel Syndrome
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive Behavioral Therapy (CBT) - three manualized sessions including one physical activity exposure session
Study: 18655472
Drug: Low-protein diet
Normalized name: low-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-protein diet (0.6 g protein/kg/day) balanced by high-calorie mix containing protein SUPRO 760 or ketosteril for 24-48 months
Study: 17217711
Drug: Losartan 50
Normalized name: LOSARTAN 50MG TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Losartan 50 mg and Irbesartan 150 mg
Study: 8097114
Drug: Raclopride 2
Normalized name: prucalopride 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride 2 mg
Study: 8097114
Drug: Raclopride 6
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Raclopride 6 mg
Study: 8097114
Drug: Raclopride 12
Normalized name: PRUCALOPRIDE
DrugBank: Prucalopride (DB06480)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Raclopride 12 mg
Study: 8097114
Drug: Raclopride (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Raclopride (all doses)
Study: 2880747
Drug: Theophylline (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (plasma concentration 25-45 mumol/l)
Study: 2880747
Drug: Theophylline (plasma
Approvals — FDA: no, EMA: no, PMDA: no
Description: Theophylline (plasma concentration 50-85 mumol/l)
Study: 2880747
Drug: Placebo (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (0 mumol/l)
Study: 23896317
Drug: High-frequency (HF)
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-frequency (HF) rTMS treatment
Study: 1775263
Drug: Haemodialysis with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemodialysis with desferrioxamine (1 g intravenously 24‐40 h before dialysis); n = 28
Study: 1775263
Drug: Haemofiltration with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemofiltration with desferrioxamine (1 g intravenously 24‐40 h before haemofiltration); n = 36
Study: 6871055
Drug: 0.8% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8% prilocaine (4 mg/kg body weight)
Study: 6871055
Drug: 1.5% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5% prilocaine (4 mg/kg body weight)
Study: 6871055
Drug: 2% prilocaine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2% prilocaine (4 mg/kg body weight)
Study: 31809905
Drug: Both dosing
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both dosing groups
Study: 21365326
Drug: A2A2 genotype
Normalized name: PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8
DrugBank: Streptococcus pneumoniae type 8 capsular polysaccharide antigen (DB10326)
Approvals — FDA: no, EMA: no, PMDA: no
Description: A2A2 genotype of the PIN3 (+16 bp) polymorphism in patients treated with chemotherapy without anthracycline
Study: 17404368
Drug: High-dose chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose chemotherapy (HDC) with autologous hematopoietic progenitor cell support (AHPCS)
Study: 17404368
Drug: Dose-dense and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-dense and dose-escalated chemotherapy with doxorubicin, paclitaxel, and cyclophosphamide
Study: 15827104
Drug: Intravenous alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous alendronate (ALN) at a dose of 125 mcg
Study: 15827104
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 35 mg for patients weighing less than 40 kg
Study: 15827104
Drug: Oral alendronate
Normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral alendronate (ALN) 70 mg for patients weighing 40 kg or more
Study: 15827104
Drug: Adverse experiences
Normalized name: iodine
DrugBank: Iodine (DB05382)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Adverse experiences from single-dose ALN
Study: 2529370
Drug: Atrial natriuretic
Normalized name: Atrial natriuretic factor
DrugBank: Atrial natriuretic peptide (DB15591)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrial natriuretic peptide (ANP) infusion at 1.2 pmol kg‐1 min‐1
Study: 385398
Drug: Diflunisal 500
Normalized name: diflunisal 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diflunisal 500 mg daily
Study: 373995
Drug: Ibuprofen 1200
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 1200 mg daily
Study: 26575256
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 1200 mg/day
Study: 26575256
Drug: Eslicarbazepine acetate
Normalized name: Eslicarbazepine Acetate
DrugBank: Eslicarbazepine (DB14575)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Eslicarbazepine acetate (ESL) 800 mg/day
Study: 26575256
Drug: Combined ESL
Normalized name: ESL
DrugBank: Eslicarbazepine acetate (DB09119)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Combined ESL arms (800 and 1200 mg/day)
Study: 20736382
Drug: Tailored Pro‐Self(©)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tailored Pro‐Self(©) exercise during and after chemotherapy
Study: 19359920
Drug: Continuous bupivacaine
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bupivacaine infusion through thoracic epidural (TEA)
Study: 19359920
Drug: Continuous bupivacaine
Normalized name: Uniphyllin Continus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous bupivacaine infusion through thoracic paravertebral block (TPVB)
Study: 16309809
Drug: 375 mg
Normalized name: niacin 375 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 375 mg of E. amoenum aqueous extract
Study: 11741108
Drug: Oral single-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral single-dose (20 mg) ketanserin
Study: 8219660
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil (9 g daily for 6 weeks)
Study: 8219660
Drug: Olive oil
Normalized name: Olive Oil
DrugBank: Olive oil (DB09567)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive oil (9 g daily for 6 weeks)
Study: 24980467
Drug: MenACWY‐CRM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM vaccine (two‐ or three‐dose primary infant series plus a single toddler dose)
Study: 24980467
Drug: MenACWY‐CRM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM vaccine (three‐dose infant primary series)
Study: 24980467
Drug: MenACWY‐CRM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM vaccine (two‐dose toddler catch‐up series)
Study: 24980467
Drug: MenACWY‐CRM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM vaccine with concomitant routine vaccines
Study: 24980467
Drug: MenACWY‐CRM vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: MenACWY‐CRM vaccine (three‐dose infant series)
Study: 22234287
Drug: High-speed power
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-speed power training (40% to 75% of 1RM); 3 sets of 4-12 reps, countermovement jump, and 1.5 kg medicine ball throwing
Study: 16996947
Drug: Piracetam (150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Piracetam (150 mg/kg daily; 300 mg/kg on the day of surgery, then orally 12 g/day up to 6 weeks after surgery)
Study: 12974696
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream (30-minute application)
Study: 11004038
Drug: Epidural anesthesia
Normalized name: Epidural Anesthesia Tray
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Epidural anesthesia (15-20 mL of 3% 2-chloroprocaine)
Study: 11004038
Drug: Spinal anesthesia
Normalized name: Bos taurus spinal cord preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Spinal anesthesia (75 mg of subarachnoid procaine with 20 microg fentanyl)
Study: 1330962
Drug: Fluoxetine (60
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine (60 mg for three days)
Study: 18341564
Drug: Lidocaine 5%
Normalized name: LIDOCAINE 5% OINT
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lidocaine 5% gel
Study: 26987963
Drug: Acupuncture combined
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture combined with conventional rehabilitation therapies
Study: 26987963
Drug: Conventional rehabilitation
Normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional rehabilitation therapies
Study: 22486133
Drug: Intravenous morphine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous morphine plus midazolam
Study: 20451192
Drug: Combined approach
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined approach of diagnostic hysteroscopy and endometrial sampling during oral contraceptive pill treatment followed by ultrashort GnRH‐ag/GnRH‐ant protocol
Study: 16138560
Drug: Candesartan (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (2 to 12 mg daily)
Study: 11809430
Drug: Aspirin (acetylsalicylic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin (acetylsalicylic acid [ASA], 1, 3, and 10 mg/min)
Study: 6294796
Drug: Cefotaxime (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefotaxime (20 mg/kg IV every 6 hr)
Study: 6294796
Drug: Gentamicin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gentamicin plus Clindamycin (1 mg/kg gentamicin IV every 8 hr plus 5 mg/kg clindamycin IV every 6 hr)
Study: 31063870
Drug: Monthly Lessons
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly Lessons (within RxWL patient platform)
Study: 28504031
Drug: Topical 0.25%
Normalized name: permethrin topical 0.25% topical kit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical 0.25% desoximetasone spray
Study: 21175030
Drug: All buccal
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All buccal tubes
Study: 17982122
Drug: Intra-patient dose
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intra-patient dose escalation of ipilimumab
Study: 17982122
Drug: Prior therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior therapy with IFNalpha-2b
Study: 17982122
Drug: Prior high-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior high-dose interleukin-2
Study: 17982122
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of high-dose steroids for treatment-related toxicities
Study: 11549530
Drug: Long-acting beta(2)-agonists
Approvals — FDA: no, EMA: no, PMDA: no
Description: Long-acting beta(2)-agonists (formoterol) with inhaled corticosteroids
Study: 11549530
Drug: Short-acting beta(2)-agonists
Normalized name: Short-acting sulfonamides
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting beta(2)-agonists (salbutamol)
Study: 9740164
Drug: Multidose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multidose formulation of epoetin alfa
Study: 9740164
Drug: Single-dose formulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose formulation of epoetin alfa
Study: 8113548
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg/day for 2 weeks)
Study: 3123540
Drug: Terbutaline 0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline 0.1 mg/kg up to 4 mg
Study: 3123540
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of cromolyn and terbutaline
Study: 29231470
Drug: Medication group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication group (yupingfeng granules prescribed for oral administration, three times a day for 2 months)
Study: 26233501
Drug: TH/lidocaine (LD;
Approvals — FDA: no, EMA: no, PMDA: no
Description: TH/lidocaine (LD; n = 30) with TH 20 mg/ml and LD 2%
Study: 21641819
Drug: Target-controlled infusion
Normalized name: Diphtheria toxin-il-3 fusion protein targeting IL-3 receptor
DrugBank: Tagraxofusp (DB14731)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Target-controlled infusion (TCI) of remifentanil (target: 7 ng/mL)
Study: 21641819
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion (CI) of remifentanil (0.3 μg/kg/min)
Study: 10399633
Drug: Gadobenate dimeglumine
Normalized name: Gadobenate Dimeglumine
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Gadobenate dimeglumine (0.2‐mmol/kg intravenous bolus)
Study: 2246974
Drug: met‐hGH (16.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: met‐hGH (16.0 mg/wk of Protropin)
Study: 6258116
Drug: ACO II
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACO II protocol (maintenance therapy after aggressive induction treatment)
Study: 31090458
Drug: Bacillus subtilis
Normalized name: Bacillus Subtilis
DrugBank: Bacillus subtilis (DB11347)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bacillus subtilis R0179 (2.5×10^9 cfu/capsule)
Study: 31090458
Drug: Bifidobacterium animalis
Normalized name: Bifidobacterium Animalis
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bifidobacterium animalis subsp. lactis B94 (5×10^9 cfu/capsule)
Study: 27918846
Drug: Soy food
Normalized name: soy acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Soy food consumption (2 daily servings)
Study: 25191771
Drug: Rivastigmine treatment
Normalized name: Rivastigmine
DrugBank: Rivastigmine (DB00989)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Rivastigmine treatment
Study: 17886253
Drug: Atrasentan 10
Normalized name: ATRASENTAN
DrugBank: Atrasentan (DB06199)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atrasentan 10 mg per day
Study: 15282985
Drug: Femoral nerve
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Femoral nerve block with 30 ml of ropivacaine 7.5 mg/ml
Study: 15282985
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment only (Paracetamol and tramadol)
Study: 17284249
Drug: Sildenafil (25,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sildenafil (25, 50, and 100 mg)
Study: 8003642
Drug: Ranitidine, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranitidine, 150 mg every morning and at bedtime
Study: 2583918
Drug: Fluoxetine 10,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine 10, 20, 40 mg